- Hepatitis D, a severe form of viral hepatitis caused by the hepatitis D Virus (HDV), continues to pose a significant global health burden, especially in regions with high rates of co-infection with Hepatitis B. The market is driven by rising awareness, improving diagnostic capabilities, and advancements in antiviral therapeutics
- The growing demand for effective diagnostic tools and treatment options is primarily fueled by increased disease surveillance efforts, the integration of hepatitis testing in routine screenings, and rising government and NGO-led initiatives targeting hepatitis elimination
- North America dominated the hepatitis D market with the largest revenue share of 26.8% in 2024, supported by well-established healthcare infrastructure, a high prevalence of Hepatitis B (which HDV requires to replicate), and ongoing clinical trials for HDV-targeted therapies. The U.S. leads the region due to early access to innovative antivirals, improved diagnostic access, and policy support for hepatitis elimination strategies
- Asia-Pacific is expected to be the fastest-growing region in the Hepatitis D market during the forecast period, owing to a high disease burden in countries such as China, India, and Mongolia, along with rising healthcare expenditure, expanding public health programs, and increasing access to HBV/HDV co-infection screening
- The chronic Hepatitis D segment dominated the hepatitis D market with a market share of 58.4% in 2024, driven by the higher disease burden and long-term complications associated with HDV co-infection, particularly in patients with chronic Hepatitis B. Chronic HDV infection accelerates liver fibrosis, cirrhosis, and the risk of hepatocellular carcinoma, necessitating consistent treatment and close clinical monitoring
